Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Acute Myeloid Leukemia | Review

The dual role of autophagy in acute myeloid leukemia

Authors: Wonhyoung Seo, Prashanta Silwal, Ik-Chan Song, Eun-Kyeong Jo

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Acute myeloid leukemia (AML) is a severe hematologic malignancy prevalent in older patients, and the identification of potential therapeutic targets for AML is problematic. Autophagy is a lysosome-dependent catabolic pathway involved in the tumorigenesis and/or treatment of various cancers. Mounting evidence has suggested that autophagy plays a critical role in the initiation and progression of AML and anticancer responses. In this review, we describe recent updates on the multifaceted functions of autophagy linking to genetic alterations of AML. We also summarize the latest evidence for autophagy-related genes as potential prognostic predictors and drivers of AML tumorigenesis. We then discuss the crosstalk between autophagy and tumor cell metabolism into the impact on both AML progression and anti-leukemic treatment. Moreover, a series of autophagy regulators, i.e., the inhibitors and activators, are described as potential therapeutics for AML. Finally, we describe the translation of autophagy-modulating therapeutics into clinical practice. Autophagy in AML is a double-edged sword, necessitating a deeper understanding of how autophagy influences dual functions in AML tumorigenesis and anti-leukemic responses.
Literature
1.
Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol. 2020;95(11):1368–98.PubMedCrossRef
2.
3.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.PubMedCrossRef
4.
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.PubMedPubMedCentralCrossRef
5.
6.
7.
8.
Joffre C, Ducau C, Poillet-Perez L, Courdy C, Mansat-De MV. Autophagy a Close Relative of AML Biology. Biology (Basel). 2021;10(6):552.
9.
Du W, Xu A, Huang Y, Cao J, Zhu H, Yang B, et al. The role of autophagy in targeted therapy for acute myeloid leukemia. Autophagy. 2021;17(10):2665–79.PubMedCrossRef
10.
Torgersen ML, Simonsen A. Autophagy: friend or foe in the treatment of fusion protein-associated leukemias? Autophagy. 2013;9(12):2175–7.PubMedCrossRef
11.
Altman JK, Szilard A, Goussetis DJ, Sassano A, Colamonici M, Gounaris E, et al. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res. 2014;20(9):2400–9.PubMedPubMedCentralCrossRef
12.
Torgersen ML, Engedal N, Boe SO, Hokland P, Simonsen A. Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. Blood. 2013;122(14):2467–76.PubMedCrossRef
13.
Mortensen M, Watson AS, Simon AK. Lack of autophagy in the hematopoietic system leads to loss of hematopoietic stem cell function and dysregulated myeloid proliferation. Autophagy. 2011;7(9):1069–70.PubMedPubMedCentralCrossRef
14.
Elzinga BM, Nyhan MJ, Crowley LC, O’Donovan TR, Cahill MR, McKenna SL. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol. 2013;88(6):455–62.PubMedCrossRef
15.
Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012;120(17):3555–62.PubMedPubMedCentralCrossRef
16.
Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARalpha oncoprotein. Autophagy. 2011;7(4):401–11.PubMedPubMedCentralCrossRef
17.
Isakson P, Bjoras M, Boe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 2010;116(13):2324–31.PubMedCrossRef
18.
Finn L, Dalovisio A, Foran J. Older patients with acute myeloid leukemia: treatment challenges and future directions. Ochsner J. 2017;17(4):398–404.PubMedPubMedCentral
19.
20.
21.
Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;161(2):192–203.PubMedCrossRef
22.
23.
Alibhai SM, Leach M, Minden MD, Brandwein J. Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13):2903–11.PubMedCrossRef
24.
Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–603.PubMedCrossRef
25.
Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.
26.
Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43(5):470–5.PubMedPubMedCentralCrossRef
27.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66.PubMedCrossRef
28.
29.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40.PubMedCrossRef
30.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64.PubMedPubMedCentralCrossRef
31.
Mupo A, Celani L, Dovey O, Cooper JL, Grove C, Rad R, et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013;27(9):1917–20.PubMedPubMedCentralCrossRef
32.
Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19(9):2482–92.PubMedCrossRef
33.
Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–70.PubMedCrossRef
34.
Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–8.PubMedCrossRef
35.
Lo-Coco F, Di Donato L, Gimema, Schlenk RF, German-Austrian Acute Myeloid Leukemia Study G, and Study Alliance L. Targeted Therapy Alone for Acute Promyelocytic Leukemia. N Engl J Med. 2016;374(12):1197–1198.
36.
Licht JD. Acute promyelocytic leukemia–weapons of mass differentiation. N Engl J Med. 2009;360(9):928–30.PubMedCrossRef
37.
Stein EM. Molecular pathways: IDH2 mutations-co-opting cellular metabolism for malignant transformation. Clin Cancer Res. 2016;22(1):16–9.PubMedCrossRef
38.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.PubMedCrossRef
39.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98.PubMedCrossRef
40.
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31.PubMedPubMedCentralCrossRef
41.
Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, et al. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transpl. 2019;54(8):1281–6.CrossRef
42.
Eisfeld AK, Kohlschmidt J, Mrozek K, Blachly JS, Walker CJ, Nicolet D, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32(6):1338–48.PubMedPubMedCentralCrossRef
43.
Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28(5):706–14.PubMedCrossRef
44.
Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, et al. Molecular definitions of autophagy and related processes. EMBO J. 2017;36(13):1811–36.PubMedPubMedCentralCrossRef
45.
46.
Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2):124–31.PubMedCrossRef
47.
48.
Frentzel J, Sorrentino D, Giuriato S. Targeting autophagy in ALK-associated cancers. Cancers (Basel). 2017;9(12):161.CrossRef
49.
50.
51.
Jacob JA, Salmani JMM, Jiang Z, Feng L, Song J, Jia X, et al. Autophagy: an overview and its roles in cancer and obesity. Clin Chim Acta. 2017;468:85–9.PubMedCrossRef
52.
53.
Ishaq M, Ojha R, Sharma AP, Singh SK. Autophagy in cancer: recent advances and future directions. Semin Cancer Biol. 2020;66:171–81.PubMedCrossRef
54.
Shibutani ST, Yoshimori T. A current perspective of autophagosome biogenesis. Cell Res. 2014;24(1):58–68.PubMedCrossRef
55.
Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107–32.PubMedCrossRef
56.
Yin Q, Feng W, Shen X, and Ju S. Regulatory effects of lncRNAs and miRNAs on autophagy in malignant tumorigenesis. Biosci Rep. 2018;38(5):BSR20180516.
57.
Castro I, Sampaio-Marques B, A CA, Sousa H, Fernandes A, Sanchez-Maldonado JM, et al. Functional genetic variants in ATG10 are associated with acute myeloid leukemia. Cancers (Basel). 2021;13(6):1344.
58.
59.
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy. 2021;17(1):1–382.PubMedPubMedCentralCrossRef
60.
61.
Koyama-Honda I, Itakura E, Fujiwara TK, Mizushima N. Temporal analysis of recruitment of mammalian ATG proteins to the autophagosome formation site. Autophagy. 2013;9(10):1491–9.PubMedCrossRef
62.
Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy. 2010;6(6):764–76.PubMedPubMedCentralCrossRef
63.
Yang Z, Huang J, Geng J, Nair U, Klionsky DJ. Atg22 recycles amino acids to link the degradative and recycling functions of autophagy. Mol Biol Cell. 2006;17(12):5094–104.PubMedPubMedCentralCrossRef
64.
Rafiq S, McKenna SL, Muller S, Tschan MP, Humbert M. Lysosomes in acute myeloid leukemia: potential therapeutic targets? Leukemia. 2021;35(10):2759–70.PubMedPubMedCentralCrossRef
65.
Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugs. Autophagy. 2019;15(5):900–7.PubMedPubMedCentralCrossRef
66.
Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Tholken M, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. Blood. 2019;133(2):168–79.PubMedCrossRef
67.
Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med. 2011;208(3):455–67.PubMedPubMedCentralCrossRef
68.
Wu F, Chen Z, Liu J, Hou Y. The Akt-mTOR network at the interface of hematopoietic stem cell homeostasis. Exp Hematol. 2021;103:15–23.PubMedCrossRef
69.
Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B. 2020;10(4):569–81.PubMedCrossRef
70.
Sumitomo Y, Koya J, Nakazaki K, Kataoka K, Tsuruta-Kishino T, Morita K, et al. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. Blood. 2016;128(12):1614–24.PubMedCrossRef
71.
Cao Y, Cai J, Zhang S, Yuan N, Fang Y, Wang Z, et al. Autophagy sustains hematopoiesis through targeting notch. Stem Cells Dev. 2015;24(22):2660–73.PubMedCrossRef
72.
Park SM, Ou J, Chamberlain L, Simone TM, Yang H, Virbasius CM, et al. U2AF35(S34F) promotes transformation by directing aberrant ATG7 Pre-mRNA 3’ end formation. Mol Cell. 2016;62(4):479–90.PubMedPubMedCentralCrossRef
73.
74.
75.
Watson AS, Riffelmacher T, Stranks A, Williams O, De Boer J, Cain K, et al. Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia. Cell Death Discov. 2015;1:15008.PubMedPubMedCentralCrossRef
76.
Jin J, Britschgi A, Schlafli AM, Humbert M, Shan-Krauer D, Batliner J, et al. Low autophagy (ATG) gene expression is associated with an immature AML blast cell phenotype and can be restored during AML differentiation therapy. Oxid Med Cell Longev. 2018;2018:1482795.PubMedPubMedCentral
77.
Schlafli AM, Isakson P, Garattini E, Simonsen A, Tschan MP. The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells. Sci Rep. 2017;7(1):12980.PubMedPubMedCentralCrossRef
78.
Bain BJ, Bene MC. Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta Haematol. 2019;141(4):232–44.PubMedCrossRef
79.
80.
Mannan A, Muhsen IN, Barragan E, Sanz MA, Mohty M, Hashmi SK, et al. Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants. Hematol Oncol Stem Cell Ther. 2020;13(4):189–201.PubMedCrossRef
81.
de The H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–60.PubMedCrossRef
82.
Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 2009;15(20):6321–6.PubMedCrossRef
83.
Simonsen A, Birkeland HC, Gillooly DJ, Mizushima N, Kuma A, Yoshimori T, et al. Alfy, a novel FYVE-domain-containing protein associated with protein granules and autophagic membranes. J Cell Sci. 2004;117(Pt 18):4239–51.PubMedCrossRef
84.
Li T, Ma R, Zhang Y, Mo H, Yang X, Hu S, et al. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Cell Death Dis. 2018;9(2):75.PubMedPubMedCentralCrossRef
85.
Zeng CW, Chen ZH, Zhang XJ, Han BW, Lin KY, Li XJ, et al. MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia. Autophagy. 2014;10(10):1726–37.PubMedPubMedCentralCrossRef
86.
Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24(2):212–24.PubMedCrossRef
87.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489–96.PubMedPubMedCentralCrossRef
88.
Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S, et al. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood. 2014;124(2):263–72.PubMedCrossRef
89.
Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death Dis. 2016;7(9): e2361.PubMedPubMedCentralCrossRef
90.
Muller AM, Duque J, Shizuru JA, Lubbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008;27(44):5759–73.PubMedCrossRef
91.
Man N, Tan Y, Sun XJ, Liu F, Cheng G, Greenblatt SM, et al. Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. Blood. 2017;129(20):2782–92.PubMedPubMedCentralCrossRef
92.
Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–42.PubMedCrossRef
93.
Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, et al. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene. 2018;37(6):787–97.PubMedCrossRef
94.
Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016;128(15):1944–58.PubMedPubMedCentralCrossRef
95.
Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Buhler C, et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018;32(10):2189–202.PubMedCrossRef
96.
97.
98.
Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019;20(13):3153.PubMedCentralCrossRef
99.
Omori I, Yamaguchi H, Miyake K, Miyake N, Kitano T, Inokuchi K. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. Exp Hematol. 2017;52:56–64.PubMedCrossRef
100.
Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20(6):1692–703.PubMedCrossRef
101.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102(8):2763–7.PubMedCrossRef
102.
Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001;98(1):241–3.PubMedCrossRef
103.
Larrue C, Heydt Q, Saland E, Boutzen H, Kaoma T, Sarry JE, et al. Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis. 2019;8(8):39.PubMedPubMedCentralCrossRef
104.
Xu J, Zheng J, Fu X, Wu W, Tao L, Li D, et al. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death. Int J Med Sci. 2019;16(5):757–65.PubMedPubMedCentralCrossRef
105.
Wang L, Yang L, Yang Z, Tang Y, Tao Y, Zhan Q, et al. Glycolytic enzyme PKM2 mediates autophagic activation to promote cell survival in NPM1-mutated leukemia. Int J Biol Sci. 2019;15(4):882–94.PubMedPubMedCentralCrossRef
106.
Zou Q, Tan S, Yang Z, Zhan Q, Jin H, Xian J, et al. NPM1 mutant mediated PML delocalization and stabilization enhances autophagy and cell survival in leukemic cells. Theranostics. 2017;7(8):2289–304.PubMedPubMedCentralCrossRef
107.
Tang Y, Tao Y, Wang L, Yang L, Jing Y, Jiang X, et al. NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia. FASEB J. 2021;35(2): e21192.PubMedCrossRef
108.
Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 2018;6(3):282–300 e2.
109.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.PubMedPubMedCentralCrossRef
110.
Luo H, Li Q, O’Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005;106(7):2452–61.PubMedCrossRef
111.
Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, et al. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021;2(2):162–85.PubMedCrossRef
112.
113.
114.
Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol. 2010;63(3):204–9.PubMedCrossRef
115.
George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci. 2021;22(19):10782.PubMedPubMedCentralCrossRef
116.
Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015;8:45.PubMedPubMedCentralCrossRef
117.
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552–5.PubMedCrossRef
118.
Quintas-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia. 2017;31(6):1296–305.PubMedCrossRef
119.
Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, et al. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis. 2017;8(7): e2927.PubMedPubMedCentralCrossRef
120.
Fitzwalter BE, Towers CG, Sullivan KD, Andrysik Z, Hoh M, Ludwig M, et al. Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover. Dev Cell. 2018;44(5):555–65.
121.
Vu TT, Stolzel F, Wang KW, Rollig C, Tursky ML, Molloy TJ, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. Leukemia. 2021;35(7):1933–48.PubMedCrossRef
122.
123.
124.
Yoshikawa K, Hamada J, Tada M, Kameyama T, Nakagawa K, Suzuki Y, et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res. 2010;31(6):401–11.PubMedCrossRef
125.
Yao Y, Chai X, Gong C, Zou L. WT1 inhibits AML cell proliferation in a p53-dependent manner. Cell Cycle. 2021;20(16):1552–60.PubMedCrossRef
126.
Zhu Y, Song D, Guo J, Jin J, Tao Y, Zhang Z, et al. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes. Cell Death Dis. 2021;12(7):655.PubMedPubMedCentralCrossRef
127.
Sanarico AG, Ronchini C, Croce A, Memmi EM, Cammarata UA, De Antoni A, et al. The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia. 2018;32(4):911–9.PubMedPubMedCentralCrossRef
128.
Wilson ER, Helton NM, Heath SE, Fulton RS, Payton JE, Welch JS, et al. Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia. 2022;36(4):935–45.PubMedCrossRef
129.
Tulstrup M, Soerensen M, Hansen JW, Gillberg L, Needhamsen M, Kaastrup K, et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nat Commun. 2021;12(1):6061.PubMedPubMedCentralCrossRef
130.
DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, et al. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021;16(5):567–76.PubMedCrossRef
131.
Pegliasco J, Hirsch P, Marzac C, Isnard F, Meniane JC, Deswarte C, et al. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia. 2022;36(1):126–37.PubMedCrossRef
132.
Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet. 2015;47(10):1131–40.PubMedCrossRef
133.
Sakai SS, Hasegawa A, Ishimura R, Tamura N, Kageyama S, Komatsu-Hirota S, et al. Loss of Atg2b and Gskip impairs the maintenance of the hematopoietic stem cell pool size. Mol Cell Biol. 2022;42(1): e0002421.PubMedCrossRef
134.
Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, et al. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017;8:15429.PubMedPubMedCentralCrossRef
135.
Liang PQ, Miao M, Liu ZG, Hu R, Jiang HN, Li C, et al. Expression of autophagy genes in acute myeloid leukemia: associations with clinical characteristics and prognosis. Neoplasma. 2018;65(5):807–14.PubMedCrossRef
136.
Huang L, Lin L, Fu X, Meng C. Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes. PeerJ. 2021;9: e11968.PubMedPubMedCentralCrossRef
137.
Chen XX, Li ZP, Zhu JH, Xia HT, Zhou H. Systematic analysis of autophagy-related signature uncovers prognostic predictor for acute myeloid leukemia. DNA Cell Biol. 2020;39(9):1595–605.PubMedPubMedCentralCrossRef
138.
Zhang B, Yang L, Wang X, Fu D. Identification of survival-related alternative splicing signatures in acute myeloid leukemia. Biosci Rep. 2021;41(7):BSR20204037.PubMedPubMedCentralCrossRef
139.
Chen XX, Zhu JH, Li ZP, Xiao HT, Zhou H. Comprehensive characterization of the prognosis value of alternative splicing events in acute myeloid leukemia. DNA Cell Biol. 2020;39(7):1243–55.PubMedCrossRef
140.
Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in cancer. Cell Rep. 2017;20(9):2215–26.PubMedCrossRef
141.
Fu D, Zhang B, Wu S, Zhang Y, Xie J, Ning W, et al. Prognosis and characterization of immune microenvironment in acute myeloid leukemia through identification of an autophagy-related signature. Front Immunol. 2021;12: 695865.PubMedPubMedCentralCrossRef
142.
Brigger D, Proikas-Cezanne T, Tschan MP. WIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells. Cell Death Dis. 2014;5: e1315.PubMedPubMedCentralCrossRef
143.
144.
Li Y, Jiang Y, Cheng J, Ma J, Li Q, Pang T. ATG5 regulates mesenchymal stem cells differentiation and mediates chemosensitivity in acute myeloid leukemia. Biochem Biophys Res Commun. 2020;525(2):398–405.PubMedCrossRef
145.
Hu X, Mei S, Meng W, Xue S, Jiang L, Yang Y, et al. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance. Cancer Lett. 2018;425:1–12.PubMedCrossRef
146.
147.
Fischer J, Rossetti S, Datta A, Eng K, Beghini A, Sacchi N. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Mol Cancer. 2015;14:7.PubMedPubMedCentralCrossRef
148.
Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A. 2010;107(8):3710–5.PubMedPubMedCentralCrossRef
149.
Wang W, Liu J, Chen K, Wang J, Dong Q, Xie J, et al. Vitamin D promotes autophagy in AML cells by inhibiting miR-17-5p-induced Beclin-1 overexpression. Mol Cell Biochem. 2021;476(11):3951–62.PubMedCrossRef
150.
Ganesan S, Palani HK, Lakshmanan V, Balasundaram N, Alex AA, David S, et al. Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death Dis. 2019;10(10):736.PubMedPubMedCentralCrossRef
151.
Zhang H, Kang J, Liu L, Chen L, Ren S, Tao Y. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy. Aging (Albany NY). 2020;12(20):20111–26.CrossRef
152.
Vandewalle V, Essaghir A, Bollaert E, Lenglez S, Graux C, Schoemans H, et al. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. J Cell Mol Med. 2021;25(1):575–85.PubMedCrossRef
153.
Bollaert E, Claus M, Vandewalle V, Lenglez S, Essaghir A, Demoulin JB, et al. MiR-15a-5p confers chemoresistance in acute myeloid leukemia by inhibiting autophagy induced by daunorubicin. Int J Mol Sci. 2021;22(10):5153.PubMedPubMedCentralCrossRef
154.
Gourvest M, Brousset P, Bousquet M. Long noncoding RNAs in acute myeloid leukemia: functional characterization and clinical relevance. Cancers (Basel). 2019;11(11):1638.CrossRef
155.
Zhang H, Liu L, Chen L, Liu H, Ren S, Tao Y. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis. Mol Oncol. 2021;15(4):1203–16.PubMedPubMedCentralCrossRef
156.
Zhang F, Li Q, Zhu K, Zhu J, Li J, Yuan Y, et al. LncRNA LINC00265/miR-485-5p/IRF2-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells. Am J Transl Res. 2020;12(6):2451–62.PubMedPubMedCentral
157.
Wang D, Zeng T, Lin Z, Yan L, Wang F, Tang L, et al. Long non-coding RNA SNHG5 regulates chemotherapy resistance through the miR-32/DNAJB9 axis in acute myeloid leukemia. Biomed Pharmacother. 2020;123: 109802.PubMedCrossRef
158.
Zhao C, Wang Y, Tu F, Zhao S, Ye X, Liu J, et al. A prognostic autophagy-related long non-coding RNA (ARlncRNA) signature in acute myeloid leukemia (AML). Front Genet. 2021;12: 681867.PubMedPubMedCentralCrossRef
159.
Gu S, Zi J, Han Q, Song C, and Ge Z. The autophagy-related long non-coding RNA signature for acute myeloid leukemia. Available at SSRN 3578746. 2020.
160.
Goncalves AC, Richiardone E, Jorge J, Polonia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance: clinical implications. Drug Resist Updat. 2021;59: 100797.PubMedCrossRef
161.
162.
Srivastava A, Srivastava P, Mathur S, Abbas S, Rai N, Tiwari S, et al. Lipid metabolism and mitochondria: cross talk in cancer. Curr Drug Targets. 2021.
163.
Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer. 2017;17(10):577–93.PubMedCrossRef
164.
Pereira O, Teixeira A, Sampaio-Marques B, Castro I, Girao H, Ludovico P. Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells. J Cell Mol Med. 2018;22(10):4807–17.PubMedPubMedCentralCrossRef
165.
166.
Kreitz J, Schonfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, et al. Metabolic plasticity of acute myeloid leukemia. Cells. 2019;8(8):805.PubMedCentralCrossRef
167.
Liu LL, Long ZJ, Wang LX, Zheng FM, Fang ZG, Yan M, et al. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res. 2013;11(11):1326–36.PubMedCrossRef
168.
Saulle E, Spinello I, Quaranta MT, Pasquini L, Pelosi E, Iorio E, et al. Targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation, induces two different related death-pathways and increases chemotherapeutic sensitivity of acute myeloid leukemia cells. Front Oncol. 2020;10: 621458.PubMedCrossRef
169.
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013;122(20):3521–32.PubMedPubMedCentralCrossRef
170.
Ghosh J, Kapur R. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia. Exp Hematol. 2017;50:13–21.PubMedPubMedCentralCrossRef
171.
Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819–28.PubMedCrossRef
172.
Darici S, Alkhaldi H, Horne G, Jorgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. J Clin Med. 2020;9(9):2934.PubMedCentralCrossRef
173.
Bosc C, Broin N, Fanjul M, Saland E, Farge T, Courdy C, et al. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nat Commun. 2020;11(1):4056.PubMedPubMedCentralCrossRef
174.
Thomas HE, Zhang Y, Stefely JA, Veiga SR, Thomas G, Kozma SC, et al. Mitochondrial complex I activity is required for maximal autophagy. Cell Rep. 2018;24(9):2404–2417 e8.
175.
Bosc C, Selak MA, Sarry JE. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab. 2017;26(5):705–7.PubMedCrossRef
176.
Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31.PubMedCrossRef
177.
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716–35.PubMedPubMedCentralCrossRef
178.
Humbert M, Seiler K, Mosimann S, Rentsch V, Sharma K, Pandey AV, et al. Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death Differ. 2021;28(8):2465–81.PubMedPubMedCentralCrossRef
179.
Guo H, Lin SY, Ren WX, Lei Q, Chen ZC, Zhang L, et al. Enhanced response of acute monocytic leukemia cells to low-dose cytarabine by 1,25-dihydroxyvitamin D3. Curr Med Sci. 2018;38(1):35–42.PubMedCrossRef
180.
Cao H, Xu Y, de Necochea-Campion R, Baylink DJ, Payne KJ, Tang X, et al. Application of vitamin D and vitamin D analogs in acute myelogenous leukemia. Exp Hematol. 2017;50:1–12.PubMedCrossRef
181.
Gocek E, Studzinski GP. The potential of vitamin D-regulated intracellular signaling pathways as targets for myeloid leukemia therapy. J Clin Med. 2015;4(4):504–34.PubMedPubMedCentralCrossRef
182.
Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: effect on haematopoiesis and immune system and clinical applications. Int J Mol Sci. 2018;19(9):2663.PubMedCentralCrossRef
183.
Cortes M, Chen MJ, Stachura DL, Liu SY, Kwan W, Wright F, et al. Developmental vitamin D availability impacts hematopoietic stem cell production. Cell Rep. 2016;17(2):458–68.PubMedPubMedCentralCrossRef
184.
Mouchel PL, Serhan N, Betous R, Farge T, Saland E, De Medina P, et al. Dendrogenin a enhances anti-leukemic effect of anthracycline in acute myeloid leukemia. Cancers (Basel). 2020;12(10):2933.CrossRef
185.
Serhan N, Mouchel PL, Medina P, Segala G, Mougel A, Saland E, et al. Dendrogenin A synergizes with cytarabine to kill acute myeloid leukemia cells in vitro and in vivo. Cancers (Basel). 2020;12(7):1725.CrossRef
186.
Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, et al. Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nat Commun. 2017;8(1):1903.PubMedPubMedCentralCrossRef
187.
Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med. 2019;131:356–69.PubMedCrossRef
188.
Spinello I, Saulle E, Quaranta MT, Pasquini L, Pelosi E, Castelli G, et al. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica. 2019;104(5):973–85.PubMedPubMedCentralCrossRef
189.
Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, et al. Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Exp Hematol. 2015;43(9):781–93.
190.
Xie N, Zhong L, Liu L, Fang Y, Qi X, Cao J, et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem Pharmacol. 2014;89(1):74–85.PubMedCrossRef
191.
Humbert M, Federzoni EA, Tschan MP. Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL. J Leukoc Biol. 2017;102(6):1357–70.PubMedCrossRef
192.
Kim Y, Eom JI, Jeung HK, Jang JE, Kim JS, Cheong JW, et al. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. Biomed Pharmacother. 2015;73:87–96.PubMedCrossRef
193.
Haghi A, Salemi M, Fakhimahmadi A, Mohammadi Kian M, Yousefi H, Rahmati M, et al. Effects of different autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy. IUBMB Life. 2021;73(1):130–45.PubMedCrossRef
194.
Dykstra KM, Fay HRS, Massey AC, Yang N, Johnson M, Portwood S, et al. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv. 2021;5(8):2087–100.PubMedCrossRef
195.
Jang JE, Eom JI, Jeung HK, Cheong JW, Lee JY, Kim JS, et al. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. Autophagy. 2017;13(4):761–2.PubMedPubMedCentralCrossRef
196.
Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, et al. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine. Autophagy. 2017;13(5):955–66.PubMedPubMedCentralCrossRef
197.
Gronningsaeter IS, Reikvam H, Aasebo E, Bartaula-Brevik S, Hernandez-Valladares M, Selheim F, et al. Effects of the autophagy-inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. J Pers Med. 2021;11(8):779.PubMedPubMedCentralCrossRef
198.
Visser N, Lourens HJ, Huls G, Bremer E, Wiersma VR. Inhibition of autophagy does not re-sensitize acute myeloid leukemia cells resistant to cytarabine. Int J Mol Sci. 2021;22(5):2337.PubMedPubMedCentralCrossRef
199.
Dupont M, Huart M, Lauvinerie C, Bidet A, Guitart AV, Villacreces A, et al. Autophagy targeting and hematological mobilization in FLT3-ITD acute myeloid leukemia decrease repopulating capacity and relapse by inducing apoptosis of committed leukemic cells. Cancers (Basel). 2022;14(2):453.CrossRef
200.
Pasquier B. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with MTOR inhibition in tumor cells. Autophagy. 2015;11(4):725–6.PubMedPubMedCentralCrossRef
201.
Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014;10(12):1013–9.PubMedCrossRef
202.
Nakatani K, Matsuo H, Harata Y, Higashitani M, Koyama A, Noura M, et al. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells. Int J Hematol. 2021;113(2):243–53.PubMedCrossRef
203.
Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy. 2017;13(1):214–5.PubMedCrossRef
204.
Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, et al. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016;128(9):1260–9.PubMedPubMedCentralCrossRef
205.
Zhang Z, Wu B, Chai W, Cao L, Wang Y, Yu Y, et al. Knockdown of WAVE1 enhances apoptosis of leukemia cells by downregulating autophagy. Int J Oncol. 2016;48(6):2647–56.PubMedCrossRef
206.
Chen SJ, Bao L, Keefer K, Shanmughapriya S, Chen L, Lee J, et al. Transient receptor potential ion channel TRPM2 promotes AML proliferation and survival through modulation of mitochondrial function, ROS, and autophagy. Cell Death Dis. 2020;11(4):247.PubMedPubMedCentralCrossRef
207.
Folkerts H, Wierenga AT, van den Heuvel FA, Woldhuis RR, Kluit DS, Jaques J, et al. Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis. Cell Death Dis. 2019;10(6):421.PubMedPubMedCentralCrossRef
208.
Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018;23(1):86–100 e6.
209.
Sivakumaren SC, Shim H, Zhang T, Ferguson FM, Lundquist MR, Browne CM, et al. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chem Biol. 2020;27(5):525–537 e6.
210.
Bago R, Malik N, Munson MJ, Prescott AR, Davies P, Sommer E, et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J. 2014;463(3):413–27.PubMedCrossRef
211.
Meunier G, Birsen R, Cazelles C, Belhadj M, Cantero-Aguilar L, Kosmider O, et al. Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis. 2020;9(10):94.PubMedPubMedCentralCrossRef
212.
Li Y, Li Y, Yin J, Wang C, Yang M, Gu J, et al. A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Lett. 2021;510:24–36.PubMedCrossRef
213.
San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC Inhibitors in Acute Myeloid Leukemia. Cancers (Basel). 2019;11(11):1794.CrossRef
214.
Huang H, Wenbing Y, Dong A, He Z, Yao R, Guo W. Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels. Front Oncol. 2019;9:1276.PubMedPubMedCentralCrossRef
215.
Ouchida AT, Li Y, Geng J, Najafov A, Ofengeim D, Sun X, et al. Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. Cell Death Dis. 2018;9(2):138.PubMedPubMedCentralCrossRef
216.
Putyrski M, Vakhrusheva O, Bonn F, Guntur S, Vorobyov A, Brandts C, et al. Disrupting the LC3 Interaction Region (LIR) Binding of Selective Autophagy Receptors Sensitizes AML Cell Lines to Cytarabine. Front Cell Dev Biol. 2020;8:208.PubMedPubMedCentralCrossRef
217.
Du Y, Bao J, Zhang MJ, Li LL, Xu XL, Chen H, et al. Targeting ferroptosis contributes to ATPR-induced AML differentiation via ROS-autophagy-lysosomal pathway. Gene. 2020;755: 144889.PubMedCrossRef
218.
Wang C, Li M, Li L, Shen X, Liu Y, and Wang S. Strongylocentrotus nudos Egg Polysaccharide induces autophagy and apoptosis in leukaemia cells by regulating mitochondrial function. J Cell Mol Med. 2020:272–283.
219.
Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012;26(6):1195–202.PubMedCrossRef
220.
Wang F, Liu Z, Zeng J, Zhu H, Li J, Cheng X, et al. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy. Leuk Res. 2015;39(12):1421–7.PubMedCrossRef
221.
Li L, Liu W, Sun Q, Zhu H, Hong M, Qian S. Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells. Oxid Med Cell Longev. 2021;2021:8877460.PubMedPubMedCentral
222.
Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 2012;120(4):858–67.PubMedPubMedCentralCrossRef
223.
Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127(7):882–92.PubMedCrossRef
224.
Jiang L, Zhao YM, Yang MZ. Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells. Oncol Lett. 2021;21(2):109.PubMedCrossRef
225.
Zhang Y, Geng Y, He J, Wu D, Zhang T, Xue L, et al. Tanshinone IIA induces apoptosis and autophagy in acute monocytic leukemia via downregulation of PI3K/Akt pathway. Am J Transl Res. 2019;11(5):2995–3006.PubMedPubMedCentral
226.
Du Y, Li K, Wang X, Kaushik AC, Junaid M, Wei D. Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells. FEBS J. 2020;287(8):1645–65.PubMedCrossRef
227.
Xia D, Zhang YT, Xu GP, Yan WW, Pan XR, Tong JH. Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells. Leuk Lymphoma. 2017;58(9):1–10.PubMedCrossRef
228.
Wu J, Hu G, Dong Y, Ma R, Yu Z, Jiang S, et al. Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells. J Cell Mol Med. 2017;21(6):1171–81.PubMedCrossRef
229.
Deren-Wagemann IE, Kuliczkowski K. Significance of apoptosis and autophagy of leukemic blasts for the outcomes of acute myeloid leukemia patients. Adv Clin Exp Med. 2019;28(7):861–9.PubMedCrossRef
230.
Wu MD, Zhang YY, Yi SY, Sun BB, Lan J, Jiang HM, et al. Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells. J Cell Mol Med. 2022;26(5):1606–20.PubMedPubMedCentralCrossRef
231.
Cornet-Masana JM, Banus-Mulet A, Carbo JM, Torrente MA, Guijarro F, Cuesta-Casanovas L, et al. Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. EBioMedicine. 2019;47:221–34.PubMedPubMedCentralCrossRef
232.
Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O’Hara J, Flomenberg N, et al. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs. 2018;36(4):657–66.PubMedPubMedCentralCrossRef
233.
Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia. 2013;27(7):1479–86.PubMedCrossRef
234.
Tiong IS, Tan P, McManus J, Cummings N, Sadawarte S, Catalano J, et al. Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. Leuk Lymphoma. 2018;59(2):493–6.PubMedCrossRef
235.
Liesveld JL, Baran A, Azadniv M, Misch H, Nedrow K, Becker M, et al. A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. Leuk Res. 2022;112: 106749.PubMedCrossRef
236.
Burnett AK, Das Gupta E, Knapper S, Khwaja A, Sweeney M, Kjeldsen L, et al. Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. Haematologica. 2018;103(10):1654–61.PubMedPubMedCentralCrossRef
237.
Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol. 2012;156(2):205–12.PubMedCrossRef
238.
Slapak CA, Desforges JF, Fogaren T, Miller KB. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol. 1992;41(3):178–83.PubMedCrossRef
239.
Paubelle E, Zylbersztejn F, Alkhaeir S, Suarez F, Callens C, Dussiot M, et al. Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure. PLoS ONE. 2013;8(6): e65998.PubMedPubMedCentralCrossRef
240.
Howard DS, Liesveld J, Phillips GL 2nd, Hayslip J, Weiss H, Jordan CT, et al. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leuk Res. 2013;37(11):1502–8.PubMedPubMedCentralCrossRef
241.
Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923–9.PubMedCrossRef
242.
Baer MR, George SL, Sanford BL, Mrozek K, Kolitz JE, Moore JO, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25(5):800–7.PubMedCrossRef
243.
Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenetics. 2020;12(1):132.PubMedPubMedCentralCrossRef
Metadata
Title
The dual role of autophagy in acute myeloid leukemia
Authors
Wonhyoung Seo
Prashanta Silwal
Ik-Chan Song
Eun-Kyeong Jo
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01262-y

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Correspondence

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Research

Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis

Review

How we treat NK/T-cell lymphomas

Correspondence

Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry

Review

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Review

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits